If you're managing diabetes, you know the drill: prick your finger to check blood sugar, maybe pee on a stick to check ketones. It's a hassle, and it only gives you a snapshot. But what if a single wearable could track both continuously, alerting you the moment something's off? That's the promise of Abbott's new device, and on Tuesday, the FDA gave it the green light.
The agency cleared Abbott Laboratories (ABT)'s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. This is a big deal for a few reasons. First, it's the first wearable in the U.S. to continuously monitor ketone levels. Second, it's the first system globally to track both blood sugar and ketones simultaneously in a single unit. So, no more juggling multiple devices or tests.
How It Works and Why It Matters
The FDA granted marketing authorization through the De Novo pathway, which is for new, low-to-moderate-risk devices that don't have a predicate. The sensor is designed to alert users when ketone levels rise, replacing those single-point urine or blood tests with continuous, real-time data. This could be a game-changer for people with type 1 diabetes, who are at risk for diabetic ketoacidosis (DKA), a dangerous condition where ketones build up in the blood.
The approval was based on a thorough review of six clinical studies involving over 600 participants. The results showed the sensor accurately tracks clinically significant ketone variations. And with up to 10 days of wear, it's not just a quick fix; it's a sustained monitoring solution.
The Pump Integration Roadmap
Abbott isn't stopping at just monitoring. The company is actively working with leading insulin pump manufacturers to connect the Libre Duo sensor with automated insulin delivery (AID) systems. The goal is to create a closed-loop system where the sensor's data automatically adjusts insulin delivery, making diabetes management more hands-off.
Here's the timeline: By the end of this year, Abbott expects the Libre Duo 10 Day to sync with the iLet from Beta Bionics Inc (BBNX) and the twiist from Sequel Med Tech. Looking ahead to 2027, the dual monitor will integrate with systems from Insulet Corp (PODD) and Tandem Diabetes Care Inc (TNDM). Additionally, Abbott is collaborating with MiniMed Group Inc (MMED) on an exclusive integration for smart dosing systems, also expected in 2027.
This is a strategic move. By integrating with multiple pump makers, Abbott is positioning its sensor as the go-to CGM for AID systems, potentially taking market share from competitors.
Analyst Take: A Competitive Threat
Wall Street is taking notice. On Wednesday, William Blair analyst Brandon Vazquez wrote, "Our initial impression of Abbott’s U.S. Libre Duo 10-day sensor clearance is that this sensor will likely be most competitive in the pediatric population once integrated with AID pumps into next year."
Vazquez also noted that the update may linger on DexCom Inc (DXCM) shares, as it creates a new competitive dynamic. DexCom has long been a leader in CGM, but Abbott's dual-sensor capability could give it an edge, especially for patients who need ketone monitoring.
At the time of publication on Wednesday, Abbott shares were trading up 0.32% to $116.30. It's a modest move, but the long-term implications are significant. As Abbott continues to expand its sensor's integrations and capabilities, the competitive landscape for diabetes tech is only going to get more interesting.
For now, the Libre Duo 10 Day represents a step forward in making diabetes management more seamless and proactive. And for patients, that's a win.
